NovoCure Limited (NVCR) IPO Opens Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
NovoCure (NVCR) Launches 12.5M Common Stock IPO
October 2, 2015 6:09 AM EDTNovoCure Limited (Nasdaq: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by NovoCure Limited and 5,000,000 shares to be sold by selling shareholders. The initial public offer is currently expected to be between $26 and $29 per share. The underwriters for the offering will... More
NovoCure (NVCR) Trims IPO Expectations
October 1, 2015 2:10 PM EDTNovoCure Ltd. (Nasdaq: NVCR) filed an amended registration with the U.S. SEC today. The company now plans to offer 7.5 million ordinary shares and sees an offering price of $23 - $24 per share, from prior expectations of offering 12.5 million shares with an expected pricing... More
